



# Vitamin D Supplementation in Children on Antiseizure Medications: High Time to Have Proper Guidelines

Kaushik Ragunathan<sup>1</sup> · Biswaroop Chakrabarty<sup>1</sup>

Received: 2 January 2023 / Accepted: 9 January 2023 / Published online: 22 February 2023  
© The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation 2023

A recent meta-analysis highlighted significantly reduced serum vitamin D levels in epileptic children receiving valproate monotherapy compared to healthy controls. Although it is not a conventional hepatic enzyme inducer, there are reports of valproate inducing CYP3A4 and CYP2A1, both involved in vitamin D catabolism [1]. Valproate activates pregnane X receptor which regulates the expression of vitamin D responsive genes [2]. Apart from its importance in bone growth and development, vitamin D also plays a significant role in the functioning of muscular, immune, and cardiovascular systems [1].

Studies by Viraraghavan et al. and Mikati et al. have shown the utility of vitamin D supplementation in children on antiseizure medications (ASMs) [3, 4]. The present study by Mishra et al. is a welcome addition in that direction, evaluating the utility of vitamin D supplementation in children on valproate monotherapy [5].

Mishra et al. studied children aged 2–12 y with new onset epilepsy on valproate monotherapy with vitamin D-sufficient status at baseline. They were randomized into 2 arms: intervention arm receiving vitamin D (600 IU/d) for a period of 90 d and a control group receiving only ASM. The median vitamin D level significantly increased and decreased, respectively, in the intervention and control arms over 3 mo [5].

Mikati et al. and Viraraghavan et al. included cases of a variety of ASMs as mono- or polytherapy. Although Viraraghavan included new-onset epilepsy cases, subjects in the study by Mikati et al. were on ASM for at least 6 mo. Viraraghavan et al. prescribed 60,000 IU/mo of vitamin D in the intervention arm, whereas Mikati et al. had two arms, one receiving 400 IU/d and another receiving 2000 IU/d

of vitamin D. Contrary to the study by Mishra et al., both of these studies included cases of vitamin D deficiency at baseline [3, 4]. Viraraghavan et al. demonstrated maintained serum vitamin D levels at 6-mo follow-up in the intervention arm compared to a significant decrease in the control arm [3]. Mikati et al. found a significant increase in both intervention groups at 1-y follow-up; however, the values were comparable in both groups. They also documented increases in bone mineral density at multiple skeletal sites in both arms [4]. The study by Mishra et al. reinforces the fact that even children with vitamin D-sufficient status show a significant fall in serum levels on ASM therapy that can be prevented by vitamin D supplementation.

The Endocrine Society recommends at least 2–3 times the RDA of vitamin D on ASM polytherapy [6]. Recent literature has unveiled possible anticonvulsant effects of vitamin D mediated by reduction in voltage-sensitive calcium channel expression, inhibition of iNOS, and suppression of inflammatory cytokines [7]. Mishra et al. did not show any difference in breakthrough seizures between the control and intervention arms; however, the follow-up is only for 90 d [5].

Thus, the current study further reiterates the utility of vitamin D supplementation in children with epilepsy and paves the way for future studies on various ASM mono- and polytherapies, including the long-term effect of vitamin D on seizure control.

## Declarations

**Conflict of Interest** None.

## References

1. Xu Z, Jing X, Li G, et al. Valproate decreases vitamin D levels in pediatric patients with epilepsy. *Seizure*. 2019;71:60–5.

✉ Biswaroop Chakrabarty  
biswaroopchakrabarty@gmail.com

<sup>1</sup> Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

2. Zhang Y, Zheng YX, Zhu JM, Zhang JM, Zheng Z. Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis. *J Zhejiang Univ Sci B*. 2015;16:611–21.
3. Viraraghavan VR, Seth A, Aneja S, Singh R, Dhanwal D. Effect of high dose vitamin d supplementation on vitamin d nutrition status of pre-pubertal children on anti-epileptic drugs - a randomized controlled trial. *Clin Nutr ESPEN*. 2019;29:36–40.
4. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan GH. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. *Neurology*. 2006;67:2005–14.
5. Mishra S, Mishra D, Mahajan B, Mantan M, Khan AM. Effect of daily vitamin D supplementation on serum vitamin D levels in children with epilepsy receiving sodium valproate monotherapy: a randomized, controlled trial. *Indian J Pediatr*. 2022. <https://doi.org/10.1007/s12098-022-04225-w>
6. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine society. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911–30.
7. Dong N, Guo HL, Hu YH, et al. Association between serum vitamin D status and the anti-seizure treatment in chinese children with epilepsy. *Front Nutr*. 2022;9:968868.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.